Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
- Registration Number
- NCT00598104
- Lead Sponsor
- Novartis
- Brief Summary
This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- History of asthma attacks
- Taking inhaled corticosteroids
- Non-smoking
Exclusion Criteria
- Women of child-bearing potential
- History of respiratory disease other than asthma
- History of severe allergy to food or drugs
- Previous use of monoclonal antibodies
- Very low or high body weight
Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 QAX576 - 2 Placebo -
- Primary Outcome Measures
Name Time Method - Forced expiratory volume in 1 second (FEV1)at baseline and until study completion - Levels of eosinophils in sputum Throughout the study
- Secondary Outcome Measures
Name Time Method - Three doses of QAX576 on time to treatment failure, plasma IL-13 levels and immunogenicity in asthmatics - Sputum biomarkers Throughout the study